Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ: MCTA) for alleged fraudulent activities related to stock promotion schemes that misled investors during the period from October 10, 2025, to November 12, 2025 [6]. Allegation Details - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [6]. - Insiders allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [6]. - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that inflated the stock price [6]. Stock Performance - Charming's share price increased from an initial public offering price of $4.00 to a peak of $29.36 per share, despite no fundamental news justifying such a rise [6]. - The stock was subject to an illicit promotion scheme that created a buying frenzy among retail investors through sensational claims made by impersonators in online forums and social media [6]. Regulatory Actions - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended as the company has not provided the necessary information to lift the suspension [6]. Legal Options for Investors - Investors who purchased Charming shares and suffered losses are encouraged to contact Bragar Eagel & Squire, P.C. for legal options, with a deadline of February 17, 2026, to apply as lead plaintiff in the lawsuit [4][6].
CHARMING ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Charming Medical Limited and Encourages Investors to Contact the Firm